DrugPatentWatch Database Preview

CARFILZOMIB - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for carfilzomib and what is the scope of carfilzomib patent protection?

Carfilzomib is the generic ingredient in one branded drug marketed by Onyx Therap and is included in one NDA. There are eleven patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Carfilzomib has two hundred and four patent family members in thirty-nine countries.

There are ten drug master file entries for carfilzomib. One supplier is listed for this compound.

Summary for CARFILZOMIB

International Patents:	204
US Patents:	11
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	10
Suppliers / Packagers:	1
Bulk Api Vendors:	57
Clinical Trials:	168
Patent Applications:	329
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CARFILZOMIB
DailyMed Link:	CARFILZOMIB at DailyMed

Pharmacology for CARFILZOMIB

Drug Class	Proteasome Inhibitor
Mechanism of Action	Proteasome Inhibitors

Synonyms for CARFILZOMIB

(2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide

(2S)-N-((1S)-1-Benzyl-2-(((1S)-3-methyl-1-(((2R)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide

(2S)-N-[(1S)-1-benzyl-2-[[(1S)-3-methyl-1-[(2R)-2-methyloxirane-2-carbonyl]butyl]amino]-2-oxo-ethyl]-4-methyl-2-[[(2S)-2-[(2-morpholinoacetyl)amino]-4-phenyl-butanoyl]amino]pentanamide

(Alphas)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-l-phe nylalaninamide

(alphas)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-l-phenylalaninamide

(alphaS)-alpha-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide

(S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide

(S)-4-Methyl-N-((S)-1-((S)-4-Methyl-1-((R)-2- Methyloxiran-2-yl)-1 -oxopentan-2-ylaMino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-MorpholinoacetaMido)-4-phenylbutanaMido)pentanaMide

72X6E3J5AR

868540-17-4

AB0008111

AB01565867_02

AC-27051

AK546882

AKOS025401910

AN-217

AOB87759

AS-17059

BC251806

BDBM50277889

BLMPQMFVWMYDKT-NZTKNTHTSA-N

C40H57N5O7

Carfilzomib (JAN/USAN/INN)

Carfilzomib (PR-171)

Carfilzomib [USAN:INN]

Carfilzomib; PR171

Carfilzomib?PR-171?/Kyprolis

Carfilzomib(PR171)

CAS-868540-17-4

CHEBI:65347

CHEMBL451887

CS-0984

CS-W004540

D08880

DB08889

DSSTox_CID_28616

DSSTox_GSID_48690

DSSTox_RID_82886

DTXSID4048690

EX-A2037

FT-0696769

GTPL7420

HY-10455

J-501773

KB-75946

KS-00000SR1

Kyprolis

Kyprolis (TN)

L-Phenylalaninamide, (alphaS)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-L-leucyl-N-((1S)-3-methyl-1-(((2R)-2-methyloxiranyl)carbonyl)butyl)-

MLS006011102

MolPort-027-950-907

N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide

NCGC00249613-01

NCGC00249613-02

NCGC00249613-03

ONO-7057

PR-171

PX-171-007

QCR-96

RL05381

S-7798

s2853

SB16813

SC-91032

SCHEMBL85165

SMR004660024

SR-01000941582

SR-01000941582-1

SW218090-2

Tox21_113079

Tox21_113079_1

UNII-72X6E3J5AR

Y0441

ZINC49841054

US Patents and Regulatory Information for CARFILZOMIB

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Onyx Therap	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714-003	Jun 7, 2018		RX	Yes	No
Onyx Therap	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714-001	Jul 20, 2012		RX	Yes	Yes			Y
Onyx Therap	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714-001	Jul 20, 2012		RX	Yes	Yes			Y	Y
Onyx Therap	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714-002	Jun 3, 2016		RX	Yes	No

International Patents for CARFILZOMIB

Country	Patent Number	Estimated Expiration
Hong Kong	1152536
Colombia	6361942
Spain	2358268
New Zealand	603739

Supplementary Protection Certificates for CARFILZOMIB

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1781688	C20160008 00189	Estonia		PRODUCT NAME: KARFILSOMIIB;REG NO/DATE: EU/1/15/1060 23.11.2015
1781688	16C0017	France		PRODUCT NAME: CARFILZOMIB; REGISTRATION NO/DATE: EU/1/15/1060 20151123
1781688	122016000032	Germany		PRODUCT NAME: CARFILZOMIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1060 20151119
1781688	CR 2016 00014	Denmark		PRODUCT NAME: CARFILZOMIB OG FARMACEUTISK ACCEPTABLE SALTE HERAF; REG. NO/DATE: EU/1/15/1060 20151123